Apimeds Pharmaceuticals US APUS
NYSE APUS
$2.92 -0.18 (-5.81%)
At close: Oct 23, 2026 · 4:00 PM EDT

Apimeds Pharmaceuticals US (APUS) Return on Equity [ROE] (2025 - 2026)

Updated

Apimeds Pharmaceuticals US (APUS) recorded Return on Equity [ROE] of -16.29% in Q2 2026, up 76.93 percentage points from -93.22% a year earlier.

Analysis

Apimeds Pharmaceuticals US (APUS) Return on Equity [ROE] (2025 - 2026) Analysis & Trends

For FY2025, Apimeds Pharmaceuticals US reported Return on Equity [ROE] of -15.91%.

  • Quarterly Return on Equity [ROE] has ranged from -93.22% in Q2 2025 to -14.97% in Q4 2025 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 19.33%
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn -
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 7.21%
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 31.52%
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 21.39%
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 83.75%
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn -18.38%
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 4.97%
10 Apimeds Pharmaceuticals US 4.41 Mn -15.23 Mn - -16.29%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -16.29%
Dec 31, 2025 -14.97%
Sep 30, 2025 -57.88%
Jun 30, 2025 -93.22%
API Access

Apimeds Pharmaceuticals US Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=APUS&period=max&api_key=YOUR_API_KEY